drugset
drugset / Trial / NCT02852395

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-48816274

NCT02852395 ↗

Phase 1 Completed 90 enrolled Janssen-Cilag International NV
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a 3-part study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of JNJ-48816274 in healthy participants after administration of single and repeated doses, and to evaluate its potential effectiveness for treating insomnia.

Timeline

Start
2016-08-13
Primary completion
2018-05-02
Completion
2018-05-02

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-48816274 Unknown 5 mg Oral
Subject JNJ-48816274 Unknown 250 mg Oral

Indications

No indication recorded.